Dr. Eric K. Singhi discusses the significance of the FDA approval of subcutaneous Opdivo for patients with solid tumors.

Adverse reactions occurring in at least 20% of patients included rash, musculoskeletal pain, constipation, cough, pruritus, nausea, edema, pyrexia, and fatigue. The recommended dose of ensartinib ...

The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) for the treatment of adults with locally advanced ...

The FDA approved ensartinib for the treatment of certain patients with ALK-positive locally advanced or metastatic non ... included rash, musculoskeletal pain, constipation, cough, pruritus ...

The combination of brain radiotherapy and chemoimmunotherapy “resulted in promising intracranial and systemic anti-tumor activity, with a manageable safety profile,” researchers wrote.

The FDA has approved subcutaneous nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) to treat a range of solid tumor malignancies.

Image: Adobe Stock The release states the drug has been approved for subcutaneous injection in the treatment of renal cell carcinoma, melanoma, non-small ... pain, pruritus, rash and cough.

FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.

Novocure today reported preliminary unaudited financial and operational results for the quarter and full year ended December 31, 2024. Novocure is a global oncology company working to extend survival ...

3 Common AEs were mainly grade 2 or less, and included rash, elevated transaminase levels, pruritus, nausea ... ALK-positive advanced or metastatic non-small cell lung cancer.

Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetrationEnrolling ...